ABEO ABEONA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ABEONA THERAPEUTICS INC reported revenue of $11.4M (up 2745.0% from a year earlier), net income of −$20.2M and diluted EPS of −$0.35; for the fiscal year ended December 2025 revenue was $5.82M.
ABEO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $5.82M, gross profit n/a, operating income −$89.4M, net income −$71.2M (margin -1223.1%), EPS $1.01
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$64.2M, net income $63.7M (margin n/a), EPS −$1.55
- Fiscal year ended Dec 2023: revenue $3.50M, gross profit n/a, operating income −$47.1M, net income $54.2M (margin 1548.2%), EPS −$2.53
- Fiscal year ended Dec 2022: revenue $1.41M, gross profit n/a, operating income −$50.9M, net income −$39.7M (margin -2807.4%), EPS −$5.53
- Fiscal year ended Dec 2021: revenue $3.00M, gross profit n/a, operating income −$89.8M, net income −$84.9M (margin -2831.2%), EPS −$0.86
ABEO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $11.4M (up 2745.0% year over year), net income −$20.2M, EPS −$0.35
- Quarter ended Mar 31, 2026: revenue $8.72M, net income −$17.1M, EPS −$0.30
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$163M, EPS −$0.36
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.16M, EPS −$0.10
- Quarter ended Jun 30, 2025: revenue $400K, net income $109M, EPS $1.71
- Quarter ended Mar 31, 2025: revenue n/a, net income −$12.0M, EPS −$0.24
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $118M, EPS $0.50
- Quarter ended Sep 30, 2024: revenue n/a, net income −$30.3M, EPS −$0.63
- Quarter ended Jun 30, 2024: revenue n/a, net income $7.41M, EPS −$0.26
- Quarter ended Mar 31, 2024: revenue n/a, net income −$31.6M, EPS −$1.16
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $91.8M, EPS −$0.59
- Quarter ended Sep 30, 2023: revenue n/a, net income −$11.8M, EPS −$0.48
- Quarter ended Jun 30, 2023: revenue $3.50M (up 250.0% year over year), net income −$16.7M, EPS −$0.92
- Quarter ended Mar 31, 2023: revenue n/a, net income −$9.11M, EPS −$0.54
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.12M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.43M, EPS −$1.00
- Quarter ended Jun 30, 2022: revenue $1.00M, net income −$4.10M, EPS $1.36
- Quarter ended Mar 31, 2022: revenue $346K, net income −$22.0M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$46.7M, EPS −$0.46
- Quarter ended Sep 30, 2021: revenue n/a, net income −$7.04M, EPS −$0.07
ABEO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$76.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$56.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$37.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$43.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$65.7M, share buybacks n/a
ABEO balance sheet
- Jun 30, 2026: cash $56.2M, total assets $180M, total liabilities $51.4M, shareholders' equity $128M, long-term debt $1.66M
- Mar 31, 2026: cash $61.4M, total assets $198M, total liabilities $53.6M, shareholders' equity $145M, long-term debt $4.75M
- Dec 31, 2025: cash $78.4M, total assets $220M, total liabilities $60.4M, shareholders' equity $159M, long-term debt $7.81M
- Sep 30, 2025: cash $82.9M, total assets $231M, total liabilities $59.9M, shareholders' equity $171M, long-term debt $10.9M
- Jun 30, 2025: cash $164M, total assets $246M, total liabilities $82.7M, shareholders' equity $164M, long-term debt $14.0M
- Mar 31, 2025: cash $15.9M, total assets $99.4M, total liabilities $58.0M, shareholders' equity $41.4M, long-term debt $11.1M
- Dec 31, 2024: cash $23.4M, total assets $109M, total liabilities $64.9M, shareholders' equity $44.0M, long-term debt $13.0M
- Sep 30, 2024: cash $15.7M, total assets $121M, total liabilities $74.8M, shareholders' equity $45.8M, long-term debt $14.2M
What is ABEO's revenue?
ABEONA THERAPEUTICS INC reported $5.82M of revenue for the fiscal year ended December 2025.
Is ABEO profitable?
No. ABEONA THERAPEUTICS INC lost $205M over the last four quarters.
What is ABEO's EPS?
Diluted earnings per share over the last four quarters were −$1.11; −$0.35 in the latest quarter.